Ovid Therapeutics Excited about Upcoming Investor Conferences
Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company focused on improving the lives of individuals affected by rare epilepsies and brain disorders, has recently shared some thrilling news about its participation in two major investor conferences this September.
Details of the Upcoming Conferences
Ovid's management team will be presenting their innovative strategies at the following events:
H.C. Wainwright 26th Annual Global Investment Conference
On September 10th at 3:30 p.m. ET, Ovid will take the stage at the H.C. Wainwright conference. Attendees can look forward to gaining insights into the company’s cutting-edge research and developments.
Cantor Global Healthcare Conference
Furthermore, Ovid will participate in a fireside chat at the Cantor Global Healthcare Conference on Tuesday, September 17th, at 1:55 p.m. ET. This interactive session will foster meaningful discussions about Ovid's mission and future plans.
Webcast Access
For those who wish to join virtually, live webcasts of both the fireside chat and the presentation will be available in the Events & Presentations section of Ovid’s website. An archived replay will also be accessible after the presentations, ensuring that stakeholders can remain informed.
About Ovid Therapeutics
Founded in New York, Ovid Therapeutics is dedicated to creating innovative therapies for rare epilepsies and brain-related disorders. The company is advancing a promising pipeline of targeted small molecules designed to tackle the underlying causes of neuronal hyperexcitability, which can lead to seizures and various neurological symptoms.
Innovative Product Pipeline
Ovid is currently focusing on several key developments:
- OV888/GV101: A powerful ROCK2 inhibitor aimed at treating cerebral cavernous malformations and other rare neurological diseases.
- OV329: A GABA-aminotransferase inhibitor that shows promise in treating patients with treatment-resistant seizures.
- OV350: A direct activator of the KCC2 transporter being investigated as a potential therapy for epilepsies and other psychiatric conditions.
For more information about these and other research initiatives, please visit Ovid Therapeutics' official website.
Stay Connected with Investor Relations
For any inquiries, investors are encouraged to contact Garret Bonney at 617-735-6093 or via email at gbonney@ovidrx.com. Ovid Therapeutics prioritizes transparent communication with its investors and is committed to keeping them informed about its progress and strategic direction.
Frequently Asked Questions
What is the purpose of the upcoming investor conferences?
The conferences are designed to provide insights into Ovid's advancements in treatments for rare epilepsies and brain conditions.
When is Ovid presenting at the H.C. Wainwright conference?
Ovid will present on September 10th at 3:30 p.m. ET.
Where can I access the webcasts of the presentations?
The live webcasts will be accessible through the Events & Presentations section of Ovid's website, along with archived replays.
What are some products in Ovid's pipeline?
Ovid is developing OV888, OV329, and OV350, each targeting specific neurological conditions and challenges.
Who can I contact for more information about Ovid's investor relations?
For inquiries regarding investor relations, you can reach out to Garret Bonney at 617-735-6093 or via email at gbonney@ovidrx.com.
